Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96GX5
UPID:
GWL_HUMAN
Alternative names:
Microtubule-associated serine/threonine-protein kinase-like
Alternative UPACC:
Q96GX5; Q5T8D5; Q5T8D7; Q8NCD6; Q96SJ5
Background:
Serine/threonine-protein kinase greatwall, also known as Microtubule-associated serine/threonine-protein kinase-like, is a pivotal regulator of mitosis entry and maintenance. It ensures the inactivation of protein phosphatase 2A (PP2A) during M phase, crucial for maintaining high cyclin-B1-CDK1 activity, by mediating phosphorylation of ARPP19 and ENSA. This protein's role extends to checkpoint recovery following DNA damage, highlighting its significance in cell cycle regulation.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase greatwall could open doors to potential therapeutic strategies.